SCYX übertreffen die 29 der letzten 40Schätzungen.
73%
Nächster Bericht
Datum des nächsten Berichts
10. März 2026
Estimate forQ4 25(Revenue/ EPS)
$8.26M
/
$0.12
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+2373.65%
/
-170.59%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+745.65%
/
-233.33%
SCYNEXIS, Inc. earnings per share and revenue
On 05. Nov. 2025, SCYX reported earnings of -0.17 USD per share (EPS) for Q3 25, beating the estimate of -0.20 USD, resulting in a 16.67% surprise. Revenue reached 334.00 tausend, compared to an expected 150.62 tausend, with a 121.75% difference. The market reacted with a -5.48% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of 0.12 USD, with revenue projected to reach 8.26 million USD, implying an decrease of -170.59% EPS, and increase of 2373.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26. Dez. 2025 For Q4 25
Estimate
-$0.49
Aktuell
-
Überraschung
-
FAQ
What were SCYNEXIS, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, SCYNEXIS, Inc. reported EPS of -$0.17, beating estimates by 16.67%, and revenue of $334.00K, 121.75% above expectations.
How did the market react to SCYNEXIS, Inc.'s Q3 2025 earnings?
The stock price moved down -5.48%, changed from $0.63 before the earnings release to $0.60 the day after.
When is SCYNEXIS, Inc. expected to report next?
The next earning report is scheduled for 10. März 2026.
What are the forecasts for SCYNEXIS, Inc.'s next earnings report?
Based on 5
analysts, SCYNEXIS, Inc. is expected to report EPS of $0.12 and revenue of $8.26M for Q4 2025.